PMS Registry
In order to understand if there is other unknown side effect during the clinical trail, the PMS (Post-Marketing Study) will be conducted to learn more treatment experiences on patients, and collect their information for further study.
No. 9 of IRPMA COP Benchmarks regulates that all PMS shall go through JIRB, IRB or Ethics Committee and must be registered on the website of IRPMA PMS registry system. It is to ensure the studies conducted on patients have been approved by JIRB, IRB and protect patient’s right of privacy. The public can also get the information and objective of the PMS through the registry system.
Company Name
Title of Study
Update Date
Pfizer Ltd. Taiwan LORLATINIB (PF-06463922) CONTINUATION PROTOCOL: AN OPEN-LABEL, SINGLE-ARM CONTINUATION STUDY FOR PARTICIPANTS WITH ALK-POSITIVE OR ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) CONTINUING FROM PFIZER SPONSORED LORLATINIB CLINICAL STUDIES 2024-01-25
Daiichi Sankyo Taiwan Ltd. A retrospective, non-interventional, multicenter study to estimate the prevalence of HER2-low and describe the standard-of-care, treatment patterns and outcome in real-world practice among unresectable and/or metastatic breast cancer patients with HER2-low status in Taiwan – the RetroBC-HER2L-TW Study. 2024-01-09
Bayer Taiwan Co., Ltd. AURIGA/An observational study program to investigate the effectiveness of intravitreal Aflibercept in diabetic macular edema and/or macular edema secondary to retinal vein occlusion in a real world setting. 2023-12-12
Novartis (Taiwan) Co., Ltd. Evaluating the Safety of Myfortic (Mycophenolate sodium) in patients with Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan population 2023-10-30
Janssen, Jahnson & Johnson Multicenter observational drug registry of Opsumit® (macitentan) in connective tissue disease associated pulmonary arterial hypertension (CTD-PAH) in real world Taiwan clinical setting 2023-10-03
Bayer Taiwan Co., Ltd Systemic treatment patterns of hepatocellular carcinoma (HCC) in Taiwan 2023-08-24
Bayer Taiwan Co., Ltd Copanlisib in Indolent Non-Hodgkin Lymphoma Patients: A Real-world Taiwan Observation Multicenter Study 2023-08-24
Bayer Taiwan Co., Ltd Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients / DAROL 2023-06-20
GSK A Phase IV, Prospective, Non-Interventional Cohort Study of Fostemsavir Based Regimen In Heavily Treatment Experienced Patient With Hiv-1 Infection In Taiwan 2023-05-24
AbbVie Biopharmaceuticals GmbH Prospective Observational Cohort study of patients with moderate to severe chronic plaque psoriasis in Taiwan 2023-03-24
   1 2 3 4 5 6 7 8